Aktuellt
SENASTE
Redeye leaves a comment following Magle’s announcement of a randomized controlled multicenter trial with leading European university hospitals to explore the efficacy of SmartPAN. We believe that positive results could accelerate uptake in key European markets and provide a foundation for future regulatory submissions, potentially including an entry into the US market.
LÄS MER
